<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088657</url>
  </required_header>
  <id_info>
    <org_study_id>MDCRC</org_study_id>
    <nct_id>NCT03088657</nct_id>
  </id_info>
  <brief_title>Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study</brief_title>
  <official_title>Mood Disorder Cohort Research Consortium (MDCRC) in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Mental Health, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Mood Disorder Cohort Research Consortium (MDCRC) study is designed as a naturalistic
      observational prospective cohort study for early-onset mood disorders (major depressive
      disorders, bipolar disorders type 1 and 2) in South Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Mood Disorder Cohort Research Consortium (MDCRC) study is designed as a naturalistic
      observational prospective cohort study for early-onset mood disorders (major depressive
      disorders, bipolar disorders type 1 and 2) in South Korea. The study subjects consist of two
      populations: 1) patients with mood disorders under 25 years old and 2) patients with mood
      disorders within 2 years of treatment under 35 years old. After successful screening, the
      subjects are evaluated using baseline assessments and serial follow-up assessments at 3-month
      intervals. Between the follow-up assessments, subjects are dictated to check their own daily
      mood status before bedtime using the eMood chart application or a paper mood diary. In
      addition, wearable activity tracker(Fitbit charge series) is applied for data collection such
      as activity, sleep, and heart rate during every moments. At the regular visits every 3
      months, inter-visit assessments are evaluated based on daily mood charts and interviews with
      patients. In addition to the daily mood chart, sleep quality, inter-visit major and minor
      mood episodes, stressful life events, and medical usage pattern with medical expenses are
      also assessed. Genomic DNA from blood is obtained for genomic analyses. From the MDCRC study,
      the clinical course, prognosis, and related factors of early-onset mood disorders can be
      clarified. The MDCRC is also able to facilitate translational research for mood disorders and
      provide a resource for the convergence study of mood disorders.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>illness severity and change in patients by using Clinical Global Impression-Bipolar score</measure>
    <time_frame>3months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores of depressive symptoms as assessed by MADRS</measure>
    <time_frame>3months</time_frame>
    <description>MADRS : Montgomery-Åsberg Depression Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of manic symptoms as assessed by YMRS</measure>
    <time_frame>3months</time_frame>
    <description>YMRS : Young Mania Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily mood chart</measure>
    <time_frame>3 months</time_frame>
    <description>subjects are dictated to check their own daily mood status before bedtime using the eMood chart application or a paper mood diary. Patients are provided a daily mood chart that asks for mood state (-3 to +3), energy level (-3 to +3), anxiety (0-3), irritability (0-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>3months</time_frame>
    <description>Daily data from wearable device by using Fitbit charge series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity</measure>
    <time_frame>3months</time_frame>
    <description>Daily data from wearable device by using Fitbit charge series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>3months</time_frame>
    <description>Daily data from wearable device by using Fitbit charge series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average monthly cost of treatment for psychiatric, medical, dental, and oriental medicinal management</measure>
    <time_frame>3months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Mood Disorders</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Major Depressive Disorder</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood 10cc
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        mood disorder patients who fulfill the criteria of the Diagnostic and Statistical Manual of
        Mental Disorders, Fifth Edition (DSM-5) for major depressive disorder, bipolar I disorder,
        or bipolar II disorder
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. under 25 years old with mood disorder

          2. under 35 years old with mood disorder within 2 years of treatment

        Exclusion Criteria:

          1. patients with intellectual disability

          2. patients with organic brain injury

          3. patients have difficulty reading and understanding the Korean language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heon-Jeong Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>'Korea University Anam Hospital' in Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heon-Jeong Lee, MD, PhD</last_name>
    <phone>+82 10 2269 7679</phone>
    <email>leehjeong@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chul-Hyun Cho, MD, PhD</last_name>
    <phone>+82 10 9167 2203</phone>
    <email>david0203@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heon-Jeong Lee</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heon-Jeong Lee, MD</last_name>
      <phone>+82 10 2269 7679</phone>
      <email>leehjeong@korea.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Cho CH, Ahn YM, Kim SJ, Ha TH, Jeon HJ, Cha B, Moon E, Park DY, Baek JH, Kang HJ, Ryu V, An H, Lee HJ. Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study. Psychiatry Investig. 2017 Jan;14(1):100-106. doi: 10.4306/pi.2017.14.1.100. Epub 2016 Dec 29.</citation>
    <PMID>28096882</PMID>
  </reference>
  <results_reference>
    <citation>Chang SM, Hong JP, Cho MJ. Economic burden of depression in South Korea. Soc Psychiatry Psychiatr Epidemiol. 2012 May;47(5):683-9. doi: 10.1007/s00127-011-0382-8. Epub 2011 Apr 28.</citation>
    <PMID>21526429</PMID>
  </results_reference>
  <results_reference>
    <citation>Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder. J Affect Disord. 2012 Jul;139(2):172-80. doi: 10.1016/j.jad.2012.01.033. Epub 2012 Mar 3.</citation>
    <PMID>22381955</PMID>
  </results_reference>
  <results_reference>
    <citation>Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry. 2006 Aug;163(8):1426-32.</citation>
    <PMID>16877657</PMID>
  </results_reference>
  <results_reference>
    <citation>Tenke CE, Kayser J, Manna CG, Fekri S, Kroppmann CJ, Schaller JD, Alschuler DM, Stewart JW, McGrath PJ, Bruder GE. Current source density measures of electroencephalographic alpha predict antidepressant treatment response. Biol Psychiatry. 2011 Aug 15;70(4):388-94. doi: 10.1016/j.biopsych.2011.02.016. Epub 2011 Apr 20.</citation>
    <PMID>21507383</PMID>
  </results_reference>
  <results_reference>
    <citation>Iosifescu DV, Greenwald S, Devlin P, Perlis RH, Denninger JW, Alpert JE, Fava M. Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand. 2008 Apr;117(4):271-6. doi: 10.1111/j.1600-0447.2008.01156.x. Epub 2008 Feb 26.</citation>
    <PMID>18307587</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang JS, Yoo CS, Yi SH, Her JY, Choi HM, Ha TH, Park T, Ha K. An integrative assessment of the psychophysiologic alterations in young women with recurrent major depressive disorder. Psychosom Med. 2012 Jun;74(5):495-500. doi: 10.1097/PSY.0b013e31824d0da0. Epub 2012 Mar 9.</citation>
    <PMID>22408133</PMID>
  </results_reference>
  <results_reference>
    <citation>Suto T, Fukuda M, Ito M, Uehara T, Mikuni M. Multichannel near-infrared spectroscopy in depression and schizophrenia: cognitive brain activation study. Biol Psychiatry. 2004 Mar 1;55(5):501-11.</citation>
    <PMID>15023578</PMID>
  </results_reference>
  <results_reference>
    <citation>Krömer SA, Kessler MS, Milfay D, Birg IN, Bunck M, Czibere L, Panhuysen M, Pütz B, Deussing JM, Holsboer F, Landgraf R, Turck CW. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci. 2005 Apr 27;25(17):4375-84.</citation>
    <PMID>15858064</PMID>
  </results_reference>
  <results_reference>
    <citation>Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry. 2007 May;22(5):418-23.</citation>
    <PMID>17048218</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang Z, Ma X, Wang Y, Wang J, Xiang B, Wu J, Deng W, Li M, Wang Q, Li T. Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population. Gen Hosp Psychiatry. 2012 Sep-Oct;34(5):571-7. doi: 10.1016/j.genhosppsych.2012.05.015. Epub 2012 Jul 12.</citation>
    <PMID>22795047</PMID>
  </results_reference>
  <results_reference>
    <citation>Kocabas NA. Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD). CNS Neurol Disord Drug Targets. 2012 May;11(3):264-72. Review.</citation>
    <PMID>22483292</PMID>
  </results_reference>
  <results_reference>
    <citation>Dreimüller N, Tadić A, Dragicevic A, Boland K, Bondy B, Lieb K, Laux G, Maier W, Müller MJ, Rao ML, Rietschel M, Röschke J, Zill P, Hiemke C. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry. 2012 May;45(3):108-13. doi: 10.1055/s-0031-1291347. Epub 2011 Nov 15.</citation>
    <PMID>22086748</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Heon-Jeong Lee, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cohort study</keyword>
  <keyword>early-onset mood disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

